Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VX-409
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VX-409 is a small molecule, subtype-selective sodium channel modulator developed by Vertex Pharmaceuticals in collaboration with GSK for the treatment of pain. Specifically targeted at inflammatory and neuropathic pain, the compound was designed to selectively inhibit voltage-gated sodium channels (Nav) involved in pain signaling while avoiding the side effects associated with non-selective blockers. VX-409 entered Phase I clinical trials in early 2007; however, development was subsequently discontinued, and the partnership shifted focus toward backup compounds within the same chemical series.
02
Targets
SCN8A (NaV1.6)
Beyond the preview
Go deeper on VX-409.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VX-409.